

订购单：7000137859

该订购单是由 Ariba Network 提交的。有关 Ariba 和 Ariba Network 的更多信息，请访问 <https://www.ariba.com>。



发件人：
China ISMO

中国
020，
No 7，898 Lane, Halei Road, R

收件人：
上海麦田公共关系咨询有限公司
200041
中国
Shanghai，上海市
成都北路 333号 招商局广场南楼 26
楼 2602室
电话：+86 (21) 22212238
传真：+86 (21) 22212266
电子邮件: nicole.yan@ubs-cn.com

订购单

(新建)

7000137859

金额：RMB272,526.00 CNY

版本：1

备注

Comment Type: Terms and Conditions

Body:*

AZ Signature & Stamp

Supplier Signature & Stamp

Standard Terms and Conditions for the Purchase of Goods and Services ("Conditions")

1. INTERPRETATION

1.1 In these Conditions the following words have the following meanings:

"AstraZeneca" means either AstraZeneca Investment (China) Co., Ltd, AstraZeneca (Wuxi) Trading Co., Ltd, AstraZeneca Pharmaceutical Co., Ltd or any other AstraZeneca affiliate incorporated in China purchasing Goods or Services from Seller;

"the Contract" means the contract between AstraZeneca and the Seller comprising (i) the Order, (ii) these Conditions and (iii) any other documents specified in the Order. Should there be any inconsistency between the documents comprising the Contract, they shall have precedence in the order listed in this definition;

"Goods" means any goods (or any part or parts thereof) agreed in the Contract to be purchased by AstraZeneca from the Seller;

"Order" means AstraZeneca's purchase order or any other written request from AstraZeneca to the Seller to supply the Goods or Services;

"parties" means AstraZeneca and the Seller and "party" shall mean one of them;

"Seller" means the person, firm or company who accepts the Order;

"Services" means the services agreed to be provided by the Seller to AstraZeneca under the terms of the Contract; and

"Specification" means the technical or other requirements (if any) for the Goods and/or Services referred to in the Order.

1.2 In these Conditions: references to any statute or statutory provision shall be construed as a reference to that statute or provision as from time

to time amended, consolidated, modified, extended, re-enacted or replaced; and references to the singular include the plural and vice versa as the context admits or requires.

2. APPLICATION OF TERMS

2.1 These Conditions shall govern the Contract to the entire exclusion of the Seller's terms or conditions. No terms or conditions endorsed upon, delivered with or contained in the Seller's quotation, acknowledgement or acceptance of order, specification or similar document will form part of the Contract and the Seller waives any right which it otherwise might have to rely on such terms and conditions.

2.2 These Conditions apply to all AstraZeneca's purchases and any variation to these Conditions shall have no effect unless expressly agreed in writing and signed by a duly authorised representative of AstraZeneca.

2.3 AstraZeneca's rights under these Conditions are in addition to the statutory terms implied by the UK Sale of Goods Act 1979, the Supply of Goods & Services Act 1982 and the Sale and Supply of Goods Act 1994.

3. QUALITY AND DESCRIPTION OF GOODS AND SERVICES

3.1 The Seller represents, warrants and undertakes to AstraZeneca that the Goods, (including without limitation their packaging and labelling) will:

3.1.1 conform as to quantity, quality and description with the particulars stated in the Contract;

3.1.2 be of sound materials and workmanship;

3.1.3 meet the Specification in all respects and be the same as any samples or patterns provided by either party and accepted by the other;

3.1.4 be capable of any standard of performance specified in the Contract;

3.1.5 comply with all statutory requirements and regulations relating to the manufacture and sale of the Goods at the time when the same are supplied; and

3.1.6 be fit for any purpose indicated in the Contract (either expressly or by implication).

3.2 If any Goods fail to comply with this Condition 3 AstraZeneca shall have any one or more of the remedies listed in Condition 12.

3.3 The Seller represents, warrants and undertakes to AstraZeneca that the Services will be performed:

3.3.1 by appropriately qualified and trained personnel with all due care and diligence and to the highest standard of quality prevailing in the industry at the time of performance; and

3.3.2 strictly in accordance with the Order and Specification.

3.4 If the personnel identified by the Seller become unavailable for whatever reason, the Seller undertakes to procure replacement personnel to perform the Services to the same or higher standard immediately.

3.5 Seller represents, warrants and undertakes that it will perform the Contract with AstraZeneca and operate its business in compliance with all applicable laws and regulations and to ethical standards that are consistent with AstraZeneca's Global Expectations of Third-Party Suppliers <http://www.astrazeneca.com/expectationsofsuppliers>, as amended from time to time, in particular those principles in the section headed "Preventing Bribery, Corruption & Conflicts of Interest". The Seller further represents, warrants and undertakes that it will not a) take any action that will cause any AstraZeneca group company to be in breach of any applicable laws for the prevention of fraud, bribery and corruption, racketeering, money laundering or terrorism, including the US Foreign Corrupt Practices Act and the UK Bribery Act and b) offer, pay, request or accept any bribe, inducement, kickback or facilitation payment, and shall not make or cause another to make any offer or payment to any individual or entity for the purpose of influencing a decision for the benefit of AstraZeneca. Any material breach or violation by Seller of these representations, warranties and undertakings shall give AstraZeneca the right to terminate the Contract with immediate effect, to be relieved of any obligations and to seek compensation from Seller.

3.6 Seller represents, warrants and undertakes that it will not directly or indirectly be involved in any illegal trade or counterfeiting activities and will have adequate controls in place to prevent any such trade or activity. Seller shall ensure storage and handling of Wastes (as defined below) in a manner which prevents unauthorised access and possible misuse and shall maintain adequate controls for proper disposal of Wastes ("Wastes" means waste material in connection with manufacture, supply or handling of the Goods and any material carrying AstraZeneca's name, insignia, symbol, trademark, trade name, logotype or similar).

Seller shall not disclose AstraZeneca's pack security features or anti-counterfeit measures to any third party including to his suppliers without prior approval of AstraZeneca and any disclosure shall be in the manner directed by AstraZeneca. Seller shall, within 24 hours from discovery, report any incident of breach of security relating to the Goods which could adversely impact AstraZeneca's reputation or compromises integrity of the Goods. Any breach of this Condition would be treated as a material breach of the Contract.

3.7 Seller represents, warrants and undertakes that any Goods or Services comply with applicable laws and regulations of the country(ies) of origin and destination, including those relating to manufacture, labelling, transportation, importation, exportation and licensing.

3.8 Audit Rights

Upon AstraZeneca's reasonable request, Seller shall allow AstraZeneca or (at AstraZeneca's reasonable discretion) a designated third party to audit Seller's premises, sites and records to verify Seller's performance and processes in relation to the maintenance of appropriate ethical standards, in accordance with the requirements of the Contract. Where AstraZeneca requires the audit is to be undertaken by a designated third party, Seller agrees to arrange for the audit to take place and to pay the fees of the designated third party for such audit. Any audit report generated shall be the property of Seller. Seller agrees that AstraZeneca shall be entitled to review such audit report and all supporting documents in relation to the audit.

4. INSPECTION AND TESTING

4.1 AstraZeneca may inspect and test the Goods at any time prior to delivery of the Goods to AstraZeneca.

4.2 If the results of such inspection or testing cause AstraZeneca to be of the opinion that the Goods do not conform or are unlikely to conform to the Order or to any Specification, AstraZeneca shall inform the Seller and the Seller shall immediately take such action as is necessary to ensure conformity and in addition AstraZeneca shall have the right to require and witness further testing and inspection.

4.3 The Seller shall remain fully responsible for the Goods and any such inspection or testing shall not diminish or otherwise affect the Seller's obligations under the Contract.

5. INDEMNITY AND INSURANCE

The Seller shall indemnify AstraZeneca in full and on demand against all actions, suits, liabilities, claims, demands, costs, charges, damages, losses and expenses suffered or incurred by AstraZeneca, or for which AstraZeneca may be liable to any third party, due to, arising from or in connection with:

- 5.1 the negligent or wilful acts or omissions of the Seller, its employees, agents or contractors in supplying, delivering and installing the Goods or performing the Services;
 - 5.2 the breach of any provision of the Contract by the Seller, its employees, agents or sub-contractors;
 - 5.3 any defect in the workmanship, materials or design of the Goods or their packaging; and
 - 5.4 any infringement or alleged infringement of any patent, copyright, registered design, design right, trade mark, trade name or other intellectual property right for or relating to the Goods or the Services unless such infringement has occurred directly as a result of any specification supplied by AstraZeneca.
- 5.5 Seller shall maintain at its own expense appropriate insurance coverage in amounts adequate to cover Seller's acts and omissions and as required by applicable law.

6. DELIVERY/PERFORMANCE

- 6.1 The Goods shall be properly packed and secured in such a manner as to reach their destination in good condition under normal conditions of transport having regard to the nature of the Goods and other relevant circumstances. The Seller shall off-load the Goods as directed by AstraZeneca.
- 6.2 The Goods shall be delivered or the Services performed by the Seller at the time or within the period specified in the Contract or, if no such date is specified, delivery shall take place within 28 days of the Order.
- 6.3 The Goods shall be delivered to or the Services performed for AstraZeneca at the address set out at the head of the Order or to or at such other place as may be specified in the Contract and in the manner specified in the Contract or as subsequently agreed in writing between the parties.
- 6.4 The Seller shall invoice AstraZeneca upon, but separately from, despatch of the Goods to AstraZeneca.
- 6.5 The Seller shall ensure that each delivery is accompanied by a delivery note which shows, inter alia, the order number, date of order, number of packages and contents and, in the case of part delivery, the outstanding balance remaining to be delivered.
- 6.6 Time for delivery of the Goods and performance of the Services shall be of the essence of the Contract.
- 6.7 Unless otherwise stipulated by AstraZeneca in the Order, deliveries shall only be accepted by AstraZeneca in normal business hours.
- 6.8 If the Goods are not delivered or the Services are not performed on time then, without prejudice to any other rights which it may have, AstraZeneca reserves the right to:
- 6.8.1 cancel the Contract in whole or in part;
 - 6.8.2 refuse to accept any subsequent delivery of the Goods or performance of the Services which the Seller attempts to make;
 - 6.8.3 recover from the Seller any expenditure reasonably incurred by AstraZeneca in obtaining the Goods or Services in substitution from another supplier; and
 - 6.8.4 claim damages for any additional direct costs, losses or expenses incurred by AstraZeneca which are attributable to the Seller's failure to deliver the Goods or perform the Services on time.
- 6.9 If the Seller requires AstraZeneca to return any packaging material to the Seller that fact must be clearly stated on any delivery note and any such packaging material will only be returned at the Seller's cost.
- 6.10 Where AstraZeneca agrees in writing to accept delivery by instalments the Contract will be construed as a single contract in respect of each instalment. Nevertheless failure by the Seller to deliver any one instalment shall entitle AstraZeneca at its option to treat the whole Contract as repudiated.
- 6.11 If Goods are delivered to AstraZeneca in excess of the quantities ordered AstraZeneca shall not be bound to pay for the excess, which will be and will remain at the Seller's risk and will be returnable at the Seller's cost.

7. RISK/PROPERTY

- 7.1 The Goods shall remain at the Seller's risk until delivery to AstraZeneca is complete (including off-loading and stacking) when, without prejudice to any right of rejection which the Customer may have under the Contract or by law, ownership of and risk in the Goods shall pass to AstraZeneca.

8. PRICE AND PAYMENT

- 8.1 The price of the Goods or Services shall be stated in the Order and unless otherwise agreed in writing by AstraZeneca shall be exclusive of value added tax but inclusive of all charges for packaging, packing, carriage, insurance and delivery of the Goods to the Purchaser and any duties, taxes, imports or levies incurred by the Seller.
- 8.2 AstraZeneca shall pay the price of the Goods or Services within a period of 60 days following receipt of the relevant invoice (which shall include the Order number and such other information as AstraZeneca shall request) unless stated otherwise in the Order.
- 8.3 AstraZeneca reserves the right to set off any amount owing at any time from the Seller to AstraZeneca against any amount payable by AstraZeneca to the Seller under the Contract.
- 8.4 AstraZeneca shall pay any VAT subject to receipt of a valid VAT invoice.
- 8.5 If AstraZeneca fails to pay within fourteen (14) days after payment is due and the Seller has issued a written reminder to AstraZeneca then the Seller shall be entitled to charge interest until actual payment at no more than two per cent (2%) per annum above the base lending rate of Lloyds Bank plc prevailing from time to time until payment is made.

9. CONFIDENTIALITY

The Seller shall, during the term of the Contract and for a period of five years thereafter, keep in strict confidence all technical or commercial know-how, specifications, inventions, processes or initiatives which are of a confidential nature and have been disclosed to the Seller by AstraZeneca or

its agents and any other confidential information concerning AstraZeneca's business or its products which the Seller may obtain and the Seller shall restrict disclosure of such confidential material to such of its employees, agents or contractors as need to know the same for the purpose of discharging the Seller's obligations to AstraZeneca and shall ensure that such employees, agents or contractors are subject to like obligations of confidentiality as bind the Seller.

10. INTELLECTUAL PROPERTY

10.1 Materials, equipment, tools, dies, moulds, copyright, design rights or any other forms of intellectual property rights in all drawings, specifications and data supplied by AstraZeneca to the Seller shall at all times be and remain the exclusive property of AstraZeneca but shall be held by the Seller in safe custody at its own risk and maintained and kept in good condition until returned to AstraZeneca and shall not be disposed of other than in accordance with AstraZeneca's written instructions, nor shall such items be used otherwise than as authorised by AstraZeneca in writing.

10.2 AstraZeneca shall own (and the Seller shall procure that AstraZeneca shall receive) all rights to any intellectual property relating to any results, designs, developments, ideas, discoveries or inventions designed, developed, made, produced or originated by the Seller or any of its employees, agents or contractors whilst performing the obligations set out in the Contract.

10.3 The Seller will observe all copyright in written material including computer software belonging to AstraZeneca or any third party and the Seller will not make any unauthorised copies of such material or software

11. TERMINATION

11.1 AstraZeneca may at any time and for any reason terminate the Contract in whole or in part by giving the Seller written notice whereupon all work on the Contract shall be discontinued and AstraZeneca shall pay to the Seller fair and reasonable compensation for work-in-progress at the time of termination but such compensation shall not include loss of profits or any consequential loss.

11.2 AstraZeneca may at any time by written notice to the Seller terminate the Contract forthwith if:

11.2.1 the Seller commits a material breach of any of the terms and conditions of the Contract and fails to remedy the breach (if capable of remedy) within 30 days of a notice from AstraZeneca specifying the breach; or

11.2.2 any distress, execution or other process is levied upon any of the Seller's assets or the Seller enters into any compromise or arrangement with its creditors, commits any act of bankruptcy or insolvency or if an order is made or an effective resolution is passed for its winding up (except for the purposes of amalgamation or reconstruction as a solvent company) or if a petition is presented to court, or if a receiver and/or manager, receiver, administrative receiver or administrator is appointed (or steps taken to make such appointment) in respect of the whole or any part of the Seller's undertaking or assets; or

11.2.3 the Seller ceases or threatens to cease to carry on its business; or

11.2.4 the financial position of the Seller deteriorates to such an extent that in the opinion of AstraZeneca the capability of the Seller adequately to fulfil its obligations under the Contract has been placed in jeopardy.

11.3 Termination of the Contract, however arising, will be without prejudice to the rights of AstraZeneca accrued prior to termination. Terms or conditions which expressly or impliedly have effect after termination will continue to be enforceable notwithstanding termination.

12. REMEDIES

12.1 Without prejudice to any other right or remedy which AstraZeneca may have, if any Goods or Services are not supplied in accordance with, or the Seller fails to comply with, any of the terms of the Contract AstraZeneca may exercise any one or more of the following remedies at its discretion, whether or not any part of the Goods or Services has been accepted by AstraZeneca:

12.1.1 to cancel the Contract and treat the Contract as having never been entered into; and/or

12.1.2 to reject the Goods or Services (in whole or in part) and in the case of Goods return them to the Seller at the Seller's risk and cost on the basis that a full refund for such Goods shall be paid forthwith by the Seller; and/or

12.1.3 at AstraZeneca's option to give the Seller the opportunity at the Seller's cost either to remedy any defect in the Goods or Services or to supply replacement Goods or Services and carry out any other necessary work to ensure that the terms of the Contract are fulfilled; and/or

12.1.4 to refuse to accept any further deliveries of the Goods or Services but without any liability to the Seller; and/or

12.1.5 to carry out at the Seller's cost any work necessary to make the Goods or Services comply with the Contract; and/or

12.1.6 to claim such damages as may have been sustained in consequence of the Seller's breaches of the Contract.

13. ASSIGNMENT, SUB-CONTRACTING AND THIRD PARTY RIGHTS

13.1 The Seller shall not assign, delegate, sub-contract, transfer, charge or otherwise dispose of all or any of its rights and responsibilities under the Contract without AstraZeneca's prior written consent.

13.2 AstraZeneca may assign, delegate, sub-contract, transfer, charge or otherwise dispose of all or any of its rights and responsibilities under the Contract to any AstraZeneca group company.

14. FORCE MAJEURE

AstraZeneca reserves the right to defer the date of delivery or payment or to cancel the Contract or reduce the volume of the Goods or Services ordered if it is prevented from or delayed in the carrying on of its business due to circumstances beyond the reasonable control of AstraZeneca including, without limitation, acts of God, governmental actions, war or national emergency, riot, civil commotion, fire, explosion, flood, epidemic, lock-outs, strikes or other labour

disputes (whether or not relating to either party's workforce), or restraints or delays affecting carriers or inability or delay in obtaining supplies of adequate or suitable materials.

15. CORPORATE INTEGRITY AGREEMENT REQUIREMENTS

15.1 Seller agrees to ensure that any employee, agent, contractor or subcontractor of Seller who is a "CIA Covered Person" shall abide by the applicable CIA requirements set forth in this Condition. A "CIA Covered Person" is any person involved in providing the following services for AstraZeneca: (i) services that involve direct promotional interaction with China based HCPs, such as contract sales personnel; (ii) call center personnel providing promotional or non-promotional information to HCPs; (iii) public relations firms and other suppliers authorized to communicate

promotional or non-promotional information on behalf of AstraZeneca; (iv) management of promotional and non-promotional speakers, speaker programs, conventions, HCP conferences and advisory boards; (v) services of scientific personnel to develop and disseminate non-promotional information about AstraZeneca products; (vi) Contract Research Organizations and Academic Research Organizations contracting with HCPs to perform studies; and (vii) authorship of articles relating to marketed products sold in PRC. CIA Covered Persons do not include individuals who are engaged solely in the provision of technical IS or IT support or who perform less than 160 hours of CIA covered services per calendar year.

15.2 Notice of CIA Covered Persons.

Seller shall provide the name, title, telephone number and email of any CIA Covered Person no later than 5 days after an individual becomes a CIA Covered Person. Notice shall be sent to Commercial.Operations@astrazeneca.com.

15.3 Obligations of CIA Covered Persons

Within 30 days of becoming a CIA Covered Person, a CIA Covered Person will be required to take a minimum of four hours of training and certify that he or she has received, read, understood and will abide by AstraZeneca's Code of Conduct. The training and certification will be provided on AstraZeneca's corporate learning management system, AZLearn. CIA Covered Persons are required to report promptly to the AstraZeneca Ethics Helpline any suspected or actual policy violations committed during the performance of CIA Covered Services. Any such report can be made, on an attributed or anonymous basis, by calling the Helpline at (866) 99 ETHICS or via the website www.AZethics.com.

16 COMPLIANCE TRAINING

16.1 Seller shall ensure that all Seller's employees, agents and sub-contractors, if applicable who are assigned by Seller to perform services for, or on behalf of AstraZeneca shall successfully complete any required compliance training as directed by AstraZeneca prior to commencing any Services for AstraZeneca.

16.2 Seller shall permit AstraZeneca to audit Seller's records regarding the successful completion of such mandatory compliance training.

16.3 Seller shall designate one individual from its senior management, or other responsible employee, acceptable to AstraZeneca, who shall be responsible for ensuring that Seller's employees, agents and subcontractors, if applicable, shall have successfully completed this mandatory compliance training and who shall certify in a form acceptable to AstraZeneca, that all employees and any agents or subcontractors retained by Seller to perform Services for, or on behalf of, AstraZeneca, have successfully completed this mandatory compliance training prior to commencing any such Services.

17 ADVERSE EVENTS

If the Seller becomes aware of an Adverse Event ("AE") involving an AstraZeneca product during the course of performing Services, the Seller shall collect and submit any required AE information by following the local reporting processes for the market where the adverse event was identified (to be provided by AstraZeneca, prior to beginning designated projects on behalf of AstraZeneca.) An "Adverse Event" is the development of an undesirable medical condition or the deterioration of a preexisting medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product.

18. GENERAL

18.1 Each right or remedy of AstraZeneca under the Contract is without prejudice to any other right or remedy of AstraZeneca whether under the Contract or not.

18.2 If any provision of the Contract is found to be wholly or partly illegal, invalid, void, voidable, unenforceable or unreasonable it shall, to the extent of such illegality, invalidity, voidness, voidability, unenforceability or unreasonableness, be deemed severable and the remaining provisions of the Contract shall continue in full force and effect.

18.3 Failure or delay by AstraZeneca in enforcing or partially enforcing any provision of the Contract will not be construed as a waiver of any of its rights under the Contract.

18.4 Any waiver by AstraZeneca of any breach of, or any default under, any provision of the Contract by the Seller will not be deemed a waiver of any subsequent breach or default and will in no way affect the other terms of the Contract.

18.5 This Contract (and any issues, disputes or claims arising out of or in connection with it) shall be governed by and construed in accordance with the PRC laws.

18.6 Any dispute arising out of this Agreement will be submitted to China International Economic and Trade Arbitration Committee ("CIETAC") for arbitration at Shanghai in accordance with its rules.

AstraZeneca

其他信息

Requester Email:	Lydia.Tan@astrazeneca.com
Supplier VAT Number:	91310118745630867T
公司代码:	CN30
采购单位名称:	CN30_CNMC

付款条件:	Payable 90 days from Invoice Receipt Date
-------	--

所有项目的送货地址	帐单接收方	接收人
阿斯利康投资（中国）有限公司	China ISMO	Yu Thea

201203 中国 020 , 上海 中国上海市张江高科技园区亮景路199号 目的地代码: CN30 电话: +86 (21) 60301821 电子邮件: Lydia.Tan@astrazeneca.com	中国 020 , No 7 , 898 Lane, Halei Road, R	阿斯利康投资 (中国) 有限公司
--	---	--------------------

行项目								
行号	计划行数	部件号/说明	类型	退货	数量 (单位)	到货日期	单价	小计
1		Not Available	物料 基于金额的行		1 (EA)	2022年3月30日	RMB272,526.00 CNY	RMB272,526.00 CNY
MA-MIE-Yu Thea-AZ医速递-20220330								
状态								
1 未确认								
其他信息								
基于金额的接收:			Yes					
请购单行号:			1					
请求人:			Tan, Lydia					
PR 编号:			PR1729203					
VAT Amount:			0.00 CNY					
PO Sending Method:			Ariba Network					
分类域:			custom					
分类代码:			1209					

订单提交时间 : 2022年3月21日 星期一 下午1:50 GMT+08:00
Ariba Network 接收时间 : 2022年3月21日 星期一 下午1:50 GMT+08:00
该订购单是由AstraZeneca AN01006719155发送和 Ariba Network 提交的。

小计 :	RMB	272,526.00	CNY
------	-----	------------	-----